|
Phase I Study of Intrathecal Topotecan Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase I Study of Intrathecal Topotecan conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Study of Intrathecal Topotecan Clinical research trials and Phase I Study of Intrathecal Topotecan healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase I Study of Intrathecal Topotecan. Phase I Study of Intrathecal Topotecan Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase I Study of Intrathecal Topotecan clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase I Study of Intrathecal Topotecan condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Study of Intrathecal Topotecan  Phase I Study of Intrathecal Topotecan
Phase I Study of Intrathecal Topotecan
For Condition: Leukemia,Lymphoma,Meningeal Neoplasms
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
Details: The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy). A safe dose of topotecan that can be recommended for intrathecal administration in subsequent phase II studies will be established in a limited dosage escalation schedule. The CSF pharmacokinetics of intrathecal topotecan will also be studied. Topotecan will be administered intrathecally on a bi-weekly basis for four to six weeks, followed by weekly administration for 1 month, twice monthly administration for four months and then monthly IT administration.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: Leukemia, lymphoma, or solid tumor with overt meningeal involvement considered refractory to conventional therapy. CSF leukemic cell count at least 5 per cubic millimeter with evidence of blast cells on cytospin or cytology required for leukemia and lymphoma patients. Tumor cells on cytospin or cytology or measurable meningeal disease on CT or MRI required for patients with solid tumors. No clinical evidence of obstructive hydrocephalus or compartmentalization of the CSF flow as documented by indium-111- or technetium-99-DPTA flow study. PRIOR/CONCURRENT THERAPY: At least 1 week since CNS therapy. Biologic Therapy: Recovery from toxic effects of prior immunotherapy required. Chemotherapy: Recovery from toxic effects of prior chemotherapy required. No concomitant therapy to treat meningeal malignancy (intrathecal or systemic). Concomitant chemotherapy to control systemic disease or bulk CNS disease allowed except: Investigational agents. Agents that penetrate the CNS (e.g., high-dose methotrexate, thiotepa, high-dose cytarabine, fluorouracil, intravenous mercaptopurine). Agents known to have serious unpredictable CNS side effects. Endocrine Therapy: Not specified. Radiotherapy: Recovery from toxic effects of prior radiotherapy required. Patient eligible if flow restored following focal radiotherapy to the blockage site. Surgery: Not specified. PATIENT CHARACTERISTICS: Age: 3 and over (older patients giving consent will be enrolled before the very young, if possible). Performance status: ECOG 0-2. Life expectancy: At least 8 weeks. Hematopoietic: See Disease Characteristics. Hepatic: Bilirubin less than 2.0 mg/dL, SGPT less than 3 times normal. Renal: Creatinine less than 1.5 mg/dL. Metabolic: Serum electrolytes (including calcium and phosphate) normal. Other: No significant systemic illness (e.g., infection). Not pregnant or lactating.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 930085; 93-C-0085
Study Start Date: February 4, 1993
Record last reviewed: January 1, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001333
Other Meningeal Neoplasms Studies:
1. UCN-01 in Treating Patients With Advanced Cancer
2. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
3. Total-Body Irradiation Plus Chemotherapy Followed By Donor Bone Marrow Transplantation in Treating Children With Hematologic Cancer
4. Evaluation, Treatment, and Natural History of Children with Cancer
5. Melphalan in Patients With Neoplastic Meningitis
Related Studies:
Other Meningeal Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase I Study of Intrathecal Topotecan
|
|
|
|
|
|
|
|
